KOSDAQBiotech & Pharma006620

DongKoo Bio & Pharma

₩3,585▲ 0.14%2026-10-02 close

Market Cap

₩100.1B

Turnover

₩100M

Volume

30,000 shares

Shares out.

28.5M

PER

3.0×

PBR

0.7×

EPS

₩1,221

Dividend Yield

3.33%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩120 per share · Prices as of the 2026-10-02 close

Report overview

Core Business Turns Loss-Making, Investment Gains Swing Net Income

DongKoo Bio & Pharma retains the top prescription share in the dermatology market, but its core operations swung to an operating loss in Q2 2026, and recent net income has been heavily driven by equity valuation swings in affiliates such as Qurient.

1
Q2 2026 operating loss of about KRW 6.45 billion marked a swing to loss, with an operating loss also recorded for cumulative H1
2
The 2025 annual net income surge to about KRW 50.2 billion stemmed mainly from non-operating items such as equity-method investment gains rather than the KRW 9.25 billion operating profit
3
The company lost the first-instance ruling in litigation over a solid-dosage GMP qualification revocation and is now in appeal, with the stay of execution running through September 12
4
Heavy reliance on generics and a high CSO (contract sales organization) fee ratio are cited as structural pressures on profitability
5
In-house and licensed-in pipeline assets including atopic dermatitis candidate NCP112 and BPH/OAB combination drug DKB17001 are advancing through clinical stages

Business structure

Founded in 1970, DongKoo Bio & Pharma is a specialty pharmaceutical maker centered on the dermatology and urology prescription markets.

According to prescription data disclosed by the company for 2025, dermatology prescription sales came to about KRW 31.46 billion with a 7.6% market share, keeping the company in the top position ahead of peers such as Dong-A ST and Chong Kun Dang, though this was a slight decline from KRW 32.12 billion in 2024.

As of H1 2026, the pharmaceutical segment accounted for KRW 116.3 billion, or 98.4% of total segment revenue, underscoring the company's near-total dependence on prescription drugs.

A defining feature of its business model is heavy use of contract sales organizations (CSOs); in Q2 2026, consolidated revenue of roughly KRW 59.4 billion included about KRW 27.2 billion in fee payments, a ratio of 45.76% that is markedly higher than at large pharmaceutical companies.

In biotechnology, the company holds the world's first stem-cell extraction kit brand 'SmartX' and the stem-cell cosmetics brand 'Cell Bloom,' and it recently signed an exclusive supply agreement for Cell Bloom in Taiwan as part of its overseas cosmetics push.

The company also pursues open-innovation investing through its technology finance subsidiary Lofty Rock Investment, with its equity stake in affiliate Qurient standing out as a notable investment outcome.

Amid the recent profitability downturn, the company has also been pruning its product lineup, permanently discontinuing production of six diabetes-drug items due to weak sales.

Earnings trend

Quarterly revenue · Operating profit

₩60.1B₩1.9B25Q2₩62B₩2.2B25Q3₩61.9B₩2.8B25Q4₩58.1B₩1.8B26Q1₩59.5B-₩6.5B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩195B₩17B2022₩215.7B₩14.6B2023₩249.3B₩12.7B2024₩242.7B₩9.2B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩60.1B	₩1.9B	3.2%
2025Q3	₩62B	₩2.2B	3.5%
2025Q4	₩61.9B	₩2.8B	4.5%
2026Q1	₩58.1B	₩1.8B	3.1%
2026Q2	₩59.5B	-₩6.5B	−10.9%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩195B	₩17B	₩6.6B	8.7%	6.5%	68.5%
2023	₩215.7B	₩14.6B	₩11.8B	6.8%	10.7%	73.0%
2024	₩249.3B	₩12.7B	₩2B	5.1%	1.9%	131.5%
2025	₩242.7B	₩9.2B	₩50.3B	3.8%	33.1%	121.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

Earnings analysis

Annual revenue rose from KRW 194.99 billion in 2022 to KRW 215.69 billion in 2023 and KRW 249.27 billion in 2024, before slipping to KRW 242.69 billion in 2025.

Operating margin, however, declined for four consecutive years, from 8.7% in 2022 to 6.8% in 2023, 5.1% in 2024, and 3.8% in 2025, reflecting steadily eroding core profitability.

Net income attributable to owners fluctuated from KRW 6.6 billion in 2022 to KRW 11.8 billion in 2023 and KRW 2.0 billion in 2024, then jumped sharply to KRW 50.3 billion in 2025 — a figure well above the KRW 9.25 billion operating profit, driven mainly by non-operating investment gains from equity-method affiliates.

Notably, operating cash flow in 2025 was negative KRW 4.29 billion, revealing a gap between the reported net-income surge and actual cash generation.

Looking at the most recent four quarters, operating profit held at KRW 2.19 billion in Q3 2025, KRW 2.80 billion in Q4 2025, and KRW 1.81 billion in Q1 2026, before abruptly reversing into an operating loss of KRW 6.45 billion in Q2 2026.

Net income attributable to owners also swung from a large gain of KRW 41.27 billion in Q4 2025 to losses of KRW 0.58 billion in Q1 2026 and KRW 6.07 billion in Q2 2026, marking two consecutive loss-making quarters.

The swing to loss was compounded in H1 2026 by gross profit falling from KRW 72.6 billion to KRW 68.0 billion year-on-year while selling and administrative expenses rose from KRW 68.4 billion to KRW 72.7 billion, alongside equity-method affiliate income flipping from a KRW 7.7 billion gain to a KRW 3.1 billion loss.

Part of the SG&A increase, however, is attributed to non-cash stock-based compensation granted to employees tied to the exercise of a Qurient call option, offering a partial explanation for the accounting impact.

Industry analysis

The domestic dermatology and urology specialty pharmaceutical market is characterized by intense generic competition and direct exposure to government drug-price cuts.

Industry observers have warned that as the government's drug-price reduction policy intensifies, profitability pressure on generic-focused small and mid-sized pharmaceutical companies is likely to grow.

DongKoo Bio & Pharma relies more heavily on contract sales organizations than on an in-house sales force, a structure that can support revenue expansion but leaves margins comparatively more exposed to fee costs than at larger pharmaceutical companies.

The company still holds the top position in the dermatology prescription market, though its market share slipped slightly, and it continues to face pursuit from rivals such as Dong-A ST, Theuj Pharm, and Chong Kun Dang.

In urology and otolaryngology, the company is pushing to expand its ranking as part of a broader portfolio diversification effort.

Meanwhile, competition among small and mid-cap domestic pharmaceutical companies to secure new-drug pipelines for structural transformation has intensified, and DongKoo, which has yet to produce a self-developed new drug, is responding with a combined strategy of in-licensing (NCP112) and internal development (DKB17001).

Outlook

In February 2026, the company signed an in-licensing agreement with Novacell Technology to bring in atopic dermatitis biologic candidate NCP112, which has received IND approval for a Phase 2 trial in Korea and is now being prepared for clinical progression.

In its core urology franchise, the dual-acting BPH/OAB combination candidate DKB17001 has completed nonclinical and drug-interaction Phase 1 studies and received IND approval for a Phase 3 trial in Korea, with pharmacokinetic Phase 1 and Phase 3 studies planned ahead.

R&D spending came to KRW 8.77 billion in H1 2026, equal to 7.5% of revenue, following full-year 2025 R&D spending of KRW 18.48 billion, or 8.0% of revenue.

However, in an administrative lawsuit over a 2024 GMP qualification revocation tied to Loxoris tablets and Glifamet tablets, the company lost the first-instance ruling in August 2026 and has since filed an appeal.

As of the August 18 amended disclosure, the enforcement of that administrative sanction is stayed through September 12, and the company is pursuing an additional stay application, making the timing and outcome of this case an important item to monitor for its earnings impact.

The disclosed suspension amount was about KRW 143 billion, equal to 66.57% of revenue at the time the sanction was issued, meaning finalization of the sanction could carry a meaningful business impact.

The company is also pursuing overseas expansion in cosmetics and healthcare, including through its exclusive supply agreement for the Cell Bloom brand in Taiwan.

Valuation

PER

3.0×

PBR

0.7×

ROE

26.0%

EPS

₩1,221

BPS

₩5,260

Dividend per share

₩120

DongKoo Bio & Pharma's share price appears to trade at a notable discount to its net asset value. This can be interpreted as reflecting the pattern in which 2025 net income surged on non-operating items such as equity-method investment gains, only for the core business to swing into an operating loss in 2026.

Because the company's earnings history alternates between periods of stable operating profit and episodes of sharp swings driven by investment-related items, earnings-based valuation multiples such as the price-to-earnings ratio can fluctuate widely depending on the nature of income recognized in a given quarter.

The company has maintained a dividend policy, but given the recent increase in earnings volatility, the sustainability of that policy going forward also warrants attention.

Overall, interpreting valuation metrics for this stock calls for distinguishing operating income from non-operating investment gains to assess the underlying quality of earnings, rather than relying on a simple numerical comparison.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

Bull factors

No.1 Franchise in the Dermatology Prescription Market

In 2025, the company retained the top position in the dermatology prescription market with prescription sales of about KRW 31.46 billion and a 7.6% share, ahead of rivals such as Dong-A ST and Chong Kun Dang.

Its long-accumulated prescription network and product lineup can serve as a competitive barrier relative to peers. The company is also seeking to expand its standing in urology and otolaryngology as part of broader prescription-base diversification.

Affiliate Equity Stakes as a Potential Asset

DongKoo Bio & Pharma has accumulated stakes in biotech ventures, including Qurient, as part of its open-innovation strategy. The 2025 net income surge stemmed from valuation gains on these holdings being reflected in earnings, meaning future changes in the market value of these stakes could again influence results.

The investment pipeline run through technology-finance subsidiary Lofty Rock Investment also remains a potential source of value.

Progress in Clinical-Stage Pipeline

Atopic dermatitis candidate NCP112 has received IND approval for a Phase 2 trial in Korea, while urology combination candidate DKB17001 has advanced to IND approval for a Phase 3 trial.

Should either candidate gain approval, commercialization synergies could be expected given the company's existing prescription network in dermatology and urology. Both candidates are directly aligned with the company's core business areas, giving the pipeline strategic coherence.

Bear factors

Core Operations Swing to Loss

The Q2 2026 operating loss of about KRW 6.45 billion broke a three-quarter streak of operating profit. Gross profit declined while SG&A expenses rose simultaneously, signaling clear margin pressure.

Operating margin fell for four straight years, from 8.7% in 2022 to 3.8% in 2025, confirming a structural weakening in profitability.

High CSO Dependence and Generic-Drug Risk

Fee payments to contract sales organizations reached 45.76% of revenue in Q2 2026, a stark contrast to roughly 1% at large pharmaceutical companies. Given the high reliance on generics, an intensifying government drug-price reduction policy raises concerns about a direct hit to revenue and margins.

In fact, the company has already permanently discontinued production of six diabetes-drug items, citing weakened profitability.

Litigation Uncertainty Over GMP Revocation

In August 2026, the company lost the first-instance ruling in an administrative lawsuit over the revocation of a solid-dosage GMP qualification.

The disclosed suspension amount is about KRW 143 billion, equal to 66.57% of revenue at the time of the sanction, meaning a final loss on appeal could carry a meaningful business impact. The stay of execution runs through September 12, making the outcome of any further stay application a key source of uncertainty.

Risk factors

Regulatory / Litigation Risk

The lawsuit over the GMP qualification revocation has moved to the appellate stage, and a final loss could result in an actual halt to manufacturing and sales of the affected items. Whether the stay of execution is extended and the appellate court's schedule are key variables for future earnings visibility.

Policy / Drug-Pricing Risk

As the government's drug-price reduction policy intensifies, the generic-heavy business structure could be directly affected in both revenue and margin terms. Given heavy reliance on CSO fees, a decline in revenue could disproportionately magnify the burden of relatively fixed cost items.

Investment Gain/Loss Volatility Risk

In recent years, net income has been driven more by investment gains and losses at equity-method affiliates than by operating profit. Should the market value of these holdings decline or affiliate performance deteriorate, net income volatility could widen again.

What to watch next

September 12, 2026
This is the current expiration date of the stay of execution on the GMP qualification revocation sanction; whether an additional stay application is granted directly affects near-term business continuity.
Around November 2026
This is when the Q3 2026 quarterly report is expected to be disclosed; investors should check whether operating income recovers from the Q2 loss and monitor gross profit and SG&A trends.
Upon updates on the appellate court proceedings
Once the schedule and outcome of the appellate proceedings over the GMP revocation are confirmed, the scope of any manufacturing/sales suspension and its earnings impact will become clearer.
Upon disclosure of NCP112 Phase 2 trial initiation
Investors should track the actual initiation timing and early progress of the Phase 2 trial for atopic dermatitis candidate NCP112, which has already received IND approval in Korea.
Upon disclosures of valuation changes in affiliates such as Qurient
Given that affiliate equity valuations have driven recent net income swings, continued monitoring of how changes in the market value of these stakes could affect upcoming quarterly results is warranted.

Overall view

DongKoo Bio & Pharma maintains a solid business foundation as the top player in the dermatology prescription market, but profitability concerns have come to the fore as its core operations swung to an operating loss in Q2 2026.

The 2025 net income surge is confirmed to have originated not from operating profit but from non-operating investment gains tied to equity-method affiliates, suggesting that net income could continue to swing widely independent of operating performance.

The administrative lawsuit over the GMP qualification revocation has moved to the appellate stage after a first-instance loss, and with the stay of execution set to expire on September 12, regulatory uncertainty remains.

Heavy reliance on CSO fees and a generic-centered revenue structure could act as structural profitability pressures amid the ongoing drug-price reduction policy.

On the other hand, clinical-stage pipeline assets such as NCP112 and DKB17001, along with the value of equity stakes in affiliates including Qurient, remain variables that could influence future earnings and corporate value.

Overall, assessing this stock calls for distinguishing operating profit from non-operating investment gains to properly weigh the quality of earnings.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.